What Is in the Literature.
Journal
Journal of clinical neuromuscular disease
ISSN: 1537-1611
Titre abrégé: J Clin Neuromuscul Dis
Pays: United States
ID NLM: 100887391
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
24
11
2022
Statut:
ppublish
Résumé
What is in the Literature focuses on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a neuropathy with challenges in diagnosis and treatment. A recent revision of diagnostic criteria (EFN/PNS criteria) has helped define clinical features of typical and atypical variants and what is not considered CIDP. Initiating pathologic factors is not known for typical CIDP or variants. New treatment approaches are based on immunologic mechanisms. Rare patients with a CIDP-like clinical pattern are found to have antibodies to proteins at and around the node of Ranvier and are not considered to be CIDP but a nodal-paranodopathy. Although occurring mainly in adults, CIDP also occurs in children. CIDP may have clinical and electrodiagnostic features that overlap with hereditary neuropathies, and the latter might show some response to treatment. Articles published in the past year that address these issues are discussed in this review.
Identifiants
pubmed: 36409336
doi: 10.1097/CND.0000000000000429
pii: 00131402-202212000-00002
doi:
Substances chimiques
Antibodies
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
68-74Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The author reports no conflicts of interest.
Références
Joint Task Force of the E and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—First Revision. J Peripher Nerv Syst. 2010;15:185–95.
Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021;26:242–268.
Athanasopoulos D, Motte J, Gruter T, et al. Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patients. Ann Clin Transl Neurol. 2021;8:1110–1121.
Querol LA, Hartung HP, Lewis RA, et al. The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-targeted therapies. Neurotherapeutics. 2022;19:864–873.
Liberatore G, De Lorenzo A, Giannotta C, et al. Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database. Neurol Sci. 2022;43:3939–3947.
Shelly S, Klein CJ, Dyck PJB, et al. Neurofascin-155 immunoglobulin subtypes: clinicopathologic associations and Neurologic outcomes. Neurology. 2021;97:e2392–e2403.
Doneddu PE, Dentoni M, Nobile-Orazio E. Atypical chronic inflammatory demyelinating polyradiculoneuropathy: recent advances on classification, diagnosis, and pathogenesis. Curr Opin Neurol. 2021;34:613–624.
Menon D, Katzberg HD, Bril V. Treatment approaches for atypical CIDP. Front Neurol. 2021;12:653734.
Hauw F, Fargeot G, Adams D, et al. Charcot-Marie-Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: an international multicentric retrospective study. Eur J Neurol. 2021;28:2846–2854.
Lukawska M, Potulska-Chromik A, Lipowska M, et al. Pediatric CIDP: diagnosis and management. A single-center experience. Front Neurol. 2021;12:667378.
Silsby M, Yiannikas C, Ng K, et al. Posturography as a biomarker of intravenous immunoglobulin efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2022;65:43–50.
Gruter T, Motte J, Bulut Y, et al. Axonal damage determines clinical disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a prospective cohort study of different CIDP subtypes and disease stages. Eur J Neurol. 2022;29:583–592.
Fanous J, Zero AM, Gilmore KJ, et al. Length-dependent changes of lower limb muscle morphology in Chronic Inflammatory Demyelinating Polyneuropathy assessed with magnetic resonance imaging. Eur J Transl Myol. 2021;31:10200.
Mork H, Motte J, Fisse AL, et al. Prevalence and determinants of pain in chronic inflammatory demyelinating polyneuropathy: results from the German INHIBIT registry. Eur J Neurol. 2022;29:2109–2120.
Querol L, Crabtree M, Herepath M, et al. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2021;268:3706–3716.
Adrichem ME, Lucke IM, Vrancken A, et al. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2022;145:1641–1652.